2007 looks set to be a pivotal year for ReGen Therapeutics with two significant price catalysts: the results of its Phase IIa clinical trial of zolpidem for the treatment of neurological dormancy, which are due in March/April, and the planned US launch of its pro-cognitive nutraceutical Colostrinin in October.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here